로딩 중...
52주 최고가 대비 57.7% 위치
Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company. It operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The company develops, manufactures, and markets products primarily in the therapeutic areas of gastroenterology, hepatology, neurology and dermatology, generic and branded generic pharmaceuticals, dentistry products, over-the-counter products, aesthetic medical devices, and eye health. The company sells its products in the United States, China, Canada, Poland, Mexico, France, South Korea, Russia, Japan, Germany, the United Kingdom, Spain, Italy, and internationally. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.
SEC 13F 공시 기준 · 2025-Q4
SEC 13F 공시 기준 데이터입니다. 실제 현재 보유 현황과 다를 수 있으며, 투자 자문·권유·추천이 아닙니다.
| 재무 항목 | 2021년 | 2022년 | 2023년 | 2024년 | 2025년 |
|---|---|---|---|---|---|
| 주요 재무실적 (USD) | |||||
| 매출액 | - | $8.12B | $8.76B | $9.63B | $10.27B |
| 영업이익 | - | $1.39B | $1.60B | $1.85B | $2.19B |
| 당기순이익 | - | $-225.0M | $-592.0M | $-46.0M | $157.0M |
| 잉여현금흐름 (FCF) | - | $-996.0M | $760.0M | $1.26B | $993.0M |
| 수익성 비율 | |||||
| 영업이익률 | - | 17.1% | 18.3% | 19.3% | 21.3% |
| 순이익률 | - | -2.8% | -6.8% | -0.5% | 1.5% |
| ROE (자기자본이익률) | - | 32.5% | 57.9% | 3.6% | -28.3% |
| ROA (자산이익률) | - | -0.9% | -2.2% | -0.2% | 0.6% |
| 성장성 비율 | |||||
| 매출 성장률 (YoY) | - | - | 7.8% | 9.9% | 6.7% |
| EPS 성장률 (YoY) | - | - | -161.3% | 92.0% | 423.1% |
| 투자 지표 & 가치배수 | |||||
| PER (주가수익배수) | - | - | - | - | 13.7x |
| PBR (주가순자산배수) | - | - | - | - | - |
| PSR (주가매출배수) | - | 0.4x | 0.3x | 0.3x | 0.2x |
| FCF Yield | - | -34.6% | 25.9% | 45.3% | 46.3% |
| 재무 건전성 (안정성) | |||||
| 부채비율 (D/E) | - | -30.01 | -21.91 | -16.90 | -37.64 |
| 유동비율 | - | 1.08 | 1.30 | 0.86 | 1.47 |
MOLINA HEALTHCARE INC
$179.86
$9.4B